Tocagen (NASDAQ:TOCA) issued its quarterly earnings results on Thursday. The company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.22, Morningstar.com reports. Tocagen had a negative net margin of 130,944.75% and a negative return on equity of 77.46%. The firm had revenue of $18.01 million for the quarter, compared to analysts’ expectations of $2.01 million.
NASDAQ TOCA traded up $0.78 on Friday, hitting $13.08. 184,400 shares of the company were exchanged, compared to its average volume of 162,660. The company has a current ratio of 6.06, a quick ratio of 6.06 and a debt-to-equity ratio of 0.56. The company has a market cap of $232.83 million, a PE ratio of -4.92 and a beta of 2.84. Tocagen has a twelve month low of $7.52 and a twelve month high of $15.80.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Granahan Investment Management Inc. MA grew its stake in Tocagen by 16.0% during the 2nd quarter. Granahan Investment Management Inc. MA now owns 42,438 shares of the company’s stock valued at $396,000 after acquiring an additional 5,839 shares in the last quarter. Bank of New York Mellon Corp grew its stake in Tocagen by 12.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 52,845 shares of the company’s stock valued at $824,000 after acquiring an additional 5,938 shares in the last quarter. Alps Advisors Inc. grew its stake in Tocagen by 22.2% during the 3rd quarter. Alps Advisors Inc. now owns 35,305 shares of the company’s stock valued at $550,000 after acquiring an additional 6,408 shares in the last quarter. Beaumont Financial Partners LLC purchased a new position in Tocagen during the 3rd quarter valued at about $212,000. Finally, Raymond James & Associates purchased a new position in Tocagen during the 2nd quarter valued at about $142,000. Hedge funds and other institutional investors own 28.00% of the company’s stock.
Several analysts have issued reports on the company. ValuEngine upgraded Tocagen from a “hold” rating to a “buy” rating in a report on Friday, November 2nd. BidaskClub downgraded Tocagen from a “buy” rating to a “hold” rating in a report on Friday, October 5th. B. Riley boosted their price objective on Tocagen from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, September 20th. Chardan Capital assumed coverage on Tocagen in a report on Thursday, August 30th. They set a “buy” rating and a $30.00 price objective on the stock. Finally, Citigroup assumed coverage on Tocagen in a report on Tuesday, September 4th. They set a “buy” rating and a $27.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $20.75.
ILLEGAL ACTIVITY WARNING: This report was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/11/09/tocagen-toca-announces-quarterly-earnings-results.html.
Tocagen Inc, a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells.
Recommended Story: How mutual funds make money
Receive News & Ratings for Tocagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen and related companies with MarketBeat.com's FREE daily email newsletter.